PharmacyCodes



DEA No. 1605 en es it fr

DEA No. 1605 Brand names, DEA No. 1605 Analogs

DEA No. 1605 Brand Names Mixture

  • For sope (sodium lauryl sulfate + stearic acid)
  • Plax anti-plaque den rinse peppermint liq (sodium benzoate + sodium lauryl sulfate + sodium salicylate)
  • Plax anti-plaque dent rinse soft mint liq (sodium benzoate + sodium lauryl sulfate + sodium salicylate)
  • Plax anti-plaque dental rinse (sodium benzoate + sodium lauryl sulfate + sodium salicylate)

DEA No. 1605 Chemical_Formula

C15H22N2O

DEA No. 1605 RX_link

http://www.rxlist.com/cgi/generic2/mepivacaine.htm

DEA No. 1605 fda sheet

DEA No. 1605 msds (material safety sheet)

DEA_No._1605 MSDS

DEA No. 1605 Synthesis Reference

No information avaliable

DEA No. 1605 Molecular Weight

246.348 g/mol

DEA No. 1605 Melting Point

150.5 oC

DEA No. 1605 H2O Solubility

Soluble (7000 mg/L)

DEA No. 1605 State

Solid

DEA No. 1605 LogP

2.674

DEA No. 1605 Dosage Forms

Liquid; Solution

DEA No. 1605 Indication

For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.

DEA No. 1605 Pharmacology

Mepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.

DEA No. 1605 Absorption

Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.

DEA No. 1605 side effects and Toxicity

The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.

DEA No. 1605 Patient Information

DEA No. 1605 Organisms Affected

Humans and other mammals